Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In October, the FDA accepted the resubmission of the biologics license application ...

Bristol Myers Squibb’sBMY performance in 2025 reflects an ongoing transition in its revenue base, with growth from newer products partially offsetting continued declines in legacy drugs. Sales from ...

The precise biological process behind the increased risk of melanoma previously remained unclear, and the study found the use of indoor tanning beds led to a nearly threefold increase in melanoma risk ...

According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at ...

Using less ipilimumab appears to make melanoma immunotherapy both safer and more effective, with dramatically better response and survival outcomes. The findings suggest that reducing side effects may ...

DENVER -- Patients who discontinued treatment for advanced kidney cancer because of immune-related adverse events (irAEs) had a trend toward better survival and longer time to treatment failure, ...

Nivolumab displayed significant RFS benefit compared with ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma. Adjuvant treatment with nivolumab (Opdivo) led to durable efficacy vs ...